Home › NDC Lookup › Ingredients › Olanzapine › 00002-4112-30
⚪image loading
(from DailyMed)

Zyprexa Olanzapine 2.5 mg Tablet, 30-count — NDC 0002-4112-30 (Billing 00002-4112-30)

by Eli Lilly and Company · 30 TABLET in 1 BOTTLE

This is a package of 30 tablets of Zyprexa Olanzapine 2.5 mg Tablet from Eli Lilly and Company, no longer marketed, no longer in the FDA NDC Directory. It is this product's only package size.

NDC 00002-4112-30
🏷️ FDA NDC (as labeled) 0002-4112-30 billing pads the labeler segment with a zero
Rx only Brand Discontinued Non-controlled ⚠ Discontinued by firm ⇄ Compare with another NDC
🗂️ FDA directory synced Oct 1, 2026 · this listing last changed Mar 13, 2024 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

This page is curated, coded, and maintained by

Compiled from public FDA, CMS, DailyMed, NADAC, and related drug data sources. Editorial policy

NDC database record

One package, one record: these facts belong to NDC 0002-4112-30 alone.

Record
FDA NDC Directory package listing · Human prescription drug
Code segments
0002 labeler · 4112 product · 30 package
Billing quantity
30 EA per package
Barcode (UPC-A, from the NDC)
3 0002411230 8
FDA record last changed
Mar 13, 2024
⚠️
Other active recalls for Olanzapine (different manufacturers) — 1 · tap to view
These affect other manufacturers’ products for the same ingredient — not necessarily the exact NDC on this page.
Class II · Nov 25, 2024 — Failed Impurities/Degradation Specifications (Macleods Pharmaceuticals Ltd) · FDA recall D-0154-2025
Each entry is an official FDA enforcement report — look up any recall number in the FDA recall database ↗
⚠️
Excluded from the active FDA NDC Directory. The labeler reported this product as discontinued, so it is excluded from the active NDC Directory. The listing was last certified through May 2025. A label may still appear on DailyMed, but the NDC is no longer in the current FDA NDC Directory. Search the FDA NDC Directory ↗

Identity & classification

Regulatory identifiers FDA, NLM and CMS codes for this package

FDA NDC (as labeled) 0002-4112-30
Product NDC 0002-4112
11-digit billing NDC 00002411230
NCPDP billing unit EA — each (per item)
Application # NDA020592
Established class (EPC) Atypical Antipsychotic
DEA schedule Non-controlled
Marketing category NDA
Marketing status Discontinued
FDA listing status Discontinued by firm (certified through May 2025)
Route ORAL
Dosage form TABLET
Substance OLANZAPINE
TE code (Orange Book) AB · RLD · RS

Drug-database identifiers Medi-Span GPI and First Databank GCN / HICL / AHFS classification

GCN Seq No 029077
GCN 15084
HICL code 011814
Ingredient (HICL) Olanzapine
HIC1 code H
Therapeutic class — broad (HIC1) Nervous System (Except Autonomic)
HIC2 code H7
Therapeutic class — intermediate (HIC2) Psychoactive Drugs (Continued 1)
HIC3 code H7T
Therapeutic class — specific (HIC3) Antipsychotic,Atypical,Dopamine,Serotonin Antagnst
AHFS code 28:16.08.04
AHFS class Atypical Antipsychotics
FDB label name ZYPREXA 2.5 MG TABLET
FDB brand name Zyprexa
Legend status F — Federal legend — prescription drug or device
Quick answers
  • GSN (GCN sequence number): 029077
  • GCN: 15084
  • HICL (First Databank): 011814
  • AHFS class code: 28:16.08.04
Why two NDCs? The FDA registers this code as 0002-4112-30 — a 4-4-2 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the labeler segment → 00002-4112-30. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

Clinical

Label name ZYPREXA 2.5 MG TABLET Ingredient Olanzapine
📖 What it is MedlinePlus · NLM

Olanzapine is used to treat schizophrenia (a mental illness that affects how a person thinks, feels and behaves) and bipolar I disorder (a disease that causes depression, mania, and other abnormal moods). Olanzapine is in a class of medications called atypical antipsychotics. It works by changing the activity of certain natural substances in the brain.

Read the full MedlinePlus article ↗
📗 Our plain-language guide HelloPharmacist
  • It treats schizophrenia and manic or mixed episodes of bipolar I disorder, and can be added to lithium or valproate. An injection form is used for sudden agitation with those condi...
  • Oral olanzapine is usually taken once a day, with or without food. Take it as your prescriber directs and don’t stop on your own. Injections are given by a healthcare professional.
  • Sleepiness, dizziness, dry mouth, constipation, increased appetite and weight gain are common. Stand up slowly, especially at first. Your prescriber will check blood sugar, cholest...
  • Call right away for fever with stiff muscles or confusion, a severe rash, fainting, seizures, uncontrolled movements, extreme thirst or urination, or thoughts of self-harm.
📖 Read our full Olanzapine guide →
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer eachPer package
Retail pharmacies payNADAC · weekly Not in the retail survey — common for institutional, discontinued, or low-volume packs.
Medicaid paysCMS SDUD · 12 mo No recent Medicaid claims on file for this NDC — rare and low-volume NDCs are suppressed in the public data.
Medicare drug plans payPart D · quarterly No Part D plan price is available for this NDC in our data.
ℹ️
No price is published for this exact package yet. CMS surveys NADAC per package size, so a different pack of the same drug often has one.
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

Packaging — all sizes for this product

Package NDCDescription Marketing startMarketing endStatus
00002-4112-30 You're viewing this Main listing 30 TABLET in 1 BOTTLE 1997-06-23 — Discontinued by firm

Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
Olanzapine 2.5 mg 00832-6078-03 Upsher-Smith 30 tablets $0.081 AB Discontinued —
Olanzapine 2.5 mg 33342-0067-07 Macleods 30 tablets $0.081 AB Availability likely —
Olanzapine 2.5 mg 60505-3110-00 Apotex 10 tablets $0.081 AB Availability likely —
Olanzapine 2.5 mg 68084-0525-01 American 1 tablet $0.081 AB Availability likely —
Olanzapine 2.5 mg 72241-0051-11 Modavar 1000 tablets $0.081 AB Availability likely —
Olanzapine 2.5 mg 72303-0835-01 HEC 30 tablets $0.081 AB Availability likely —
Olanzapine 2.5 mg 72603-0154-01 NorthStar 30 tablets $0.081 AB Availability likely —
Olanzapine 2.5 mg 00615-8243-39 NCS 30 tablets — AB FDA listed —
Olanzapine 2.5 mg 13668-0166-01 Torrent 100 tablets — AB FDA listed —
Olanzapine 2.5 mg 55111-0163-01 Dr. 100 tablets — AB FDA listed —
Olanzapine 2.5 mg 60429-0620-10 Golden 1000 tablets — AB FDA listed —
Zyprexa 2.5 mg 61269-0630-30 H2-Pharma 30 tablets — AB FDA listed —
Olanzapine 2.5 mg 63187-0453-30 Proficient 30 tablets — AB FDA listed —
Olanzapine 2.5 mg 65862-0561-01 Aurobindo 100 tablets — AB FDA listed —
Olanzapine 2.5 mg 67046-0539-03 Coupler 30 tablets — AB FDA listed —
Olanzapine 2.5 mg 67046-1611-03 Coupler 30 tablets — AB FDA listed —
Olanzapine 2.5 mg 67877-0172-01 Ascend 100 tablets — AB FDA listed —
Olanzapine 2.5 mg 68788-4012-03 Preferred 30 tablets — AB FDA listed —
Olanzapine 2.5 mg 70518-3568-00 REMEDYREPACK 30 tablets — AB FDA listed —
Olanzapine 2.5 mg 71209-0073-01 Cadila 30 tablets — AB FDA listed —
Olanzapine 2.5 mg 71335-1760-01 Bryant 30 tablets — AB FDA listed —
Olanzapine 2.5 mg 72189-0478-30 Direct_Rx 30 tablets — AB FDA listed —
Zyprexa 2.5 mgthis 00002-4112-30 Eli 30 tablets — AB Discontinued —
About this product: this is the brand-name version. FDA-approved generic versions are listed, and recent pricing/market data suggests they may be available.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

Availability & generic status

📍
2026
Currently FDA-listed
listed with the FDA
🔓
·
Generic versions listed
see equivalents
✅Generic appears available

FDA-approved generic versions are listed, and recent pricing/market data suggests they may be available — see Therapeutic equivalents.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

🧪 Avoiding an ingredient? See Olanzapine inactive ingredients by manufacturer: every current product's list side by side, so you can ask your pharmacy for the version that does not list it.

Loading inactive ingredients from the official FDA label in the background. No external source is being called by this page request.
Where does this data come from?
Source: official FDA Structured Product Labeling (SPL) via DailyMed and the openFDA label index. Structured IACT rows and label-wide narrative are kept separate; availability and product-level specificity depend on the submitted label.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

Manufacturer & labeler

LabelerEli Lilly and Company
Application holderCHEPLAPHARM REGISTRATION GMBH
FDA applicationNDA020592 (NDA)
Labeler code00002
Product typeHuman Prescription Drug
Portfolio192 products on file

More NDCs from Eli Lilly and Company labeler code 00002

The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

Full prescribing information FDA SPL

The complete FDA label for this product — the official prescribing information, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
📄 FDA label
📄 FDA label 19 words ▾

No FDA label is on file for this product yet. Labels load from openFDA / DailyMed and refresh weekly.

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA.

Medicare Part D spend CMS · PART D · 2026 (Q1)

Medicare Part D (outpatient prescription) spending for Zyprexa — the program that covers self-administered drugs. 2 manufacturers.
⚠️ Drug-level data: CMS publishes Part D spending by drug, not by NDC — these figures combine every manufacturer, strength and package size sold under the name Zyprexa. That’s a different level of aggregation than the Medicaid card above, which is specific to this exact 11-digit NDC (pack size included), so the two aren’t directly comparable.
Period
Total Part D spend
$1.31M
Claims incl. refills
910
Beneficiaries
404
Spend / beneficiary
$3,241.27
Spend / claim
$1,438.98
Trend by period
💵 About the dollar figures: spending is what Part D plans paid before confidential manufacturer rebates, so the program’s real net cost is lower. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part D Spending by Drug (data.cms.gov), updated quarterly.

Reported adverse events (FAERS)

Read carefully: FAERS reports are voluntary and unverified. Counts are not incidence, do not establish causation, are subject to reporting bias, and cannot be used to compare one drug to another. Shown for signal context only. Reports for Zyprexa (this brand).

Top reported reactions

Weight Increased6,755
Diabetes Mellitus5,380
Toxicity To Various Agents4,187
Drug Interaction4,180
Nausea4,032
Somnolence3,945
Fatigue3,588

Age at onset

Neonate318
Infant79
Child284
Adolescent571
Adult8,573
Elderly2,683

Reporter sex

106,103 reports
Male · 50%
Female · 49%
Unknown · 1%

Serious outcomes

Hospitalization46,828
Death13,100
Life-threatening8,621
Disabling3,539
Reports over time (by year) — tap or hover for the count & year
2019 2021 2023 2026 7,083 0
Most recent year is provisional (FAERS lags ~3 months).
Where does this data come from?
Adverse-event reports from the FDA Adverse Event Reporting System (FAERS) via openFDA. FAERS reports are voluntary and unverified — counts are not incidence and don’t establish causation.

About this NDC listing & data coverage

Finished prescription product No longer marketed (per FDA listing data)
What data is (and isn’t) available for this NDC — tap to expand
NDC identity (package / product / labeler codes) ✓ Available
Labeler ✓ Available
Product & package description ✓ Available
Marketing category & status ✓ Available
Active ingredient / dosage form / route ✓ Available
FDA label (SPL via DailyMed) — Not published for this NDC No structured label is linked to this listing in DailyMed/openFDA.
Package photos — Not published for this NDC No photo available yet for this listing.
Inactive ingredients (structured) — Not published for this NDC The labeler did not submit a structured excipient list, or no SPL is available.
NADAC pharmacy acquisition price (CMS) — Not published for this NDC CMS publishes NADAC only for NDCs reported in its retail-pharmacy survey.
Orange Book / therapeutic-equivalence data ✓ Available
HCPCS J-code billing crosswalk — Not published for this NDC Most self-administered / retail products have no J-code — that is normal.
Medicaid utilization (CMS SDUD) — Not published for this NDC CMS reports utilization only for NDCs with Medicaid claims above its privacy threshold.
“Not published” reflects what the public FDA / CMS / NLM sources provide for this exact package code — it is a property of the data feeds, not a judgment about the product.

Questions about this listing

Why is there no price listed?
The pricing shown on our NDC pages comes from CMS NADAC, a voluntary survey of retail community pharmacy invoices. CMS does not publish a NADAC for every NDC — packages outside the retail survey (institutional and hospital products, bulk packages, discontinued items, and many OTC items) may never receive one. A missing price reflects the survey's scope, not this product's actual cost, and does not mean the product is free or unavailable.
Why is there no full label on this page?
No structured FDA label (SPL) is currently linked to this NDC in DailyMed/openFDA. That can happen with older listings, certain OTC and repackaged products, and recently updated listings whose label has not yet propagated. The listing itself is still valid — this page shows everything the public feeds provide for this package.
What does the discontinued status mean for this NDC?
The labeler reported a marketing end date (or the listing was delisted), so this specific package is no longer actively marketed. Remaining stock may still be dispensed for a time, and the NDC stays valid for historical records and claims — but data feeds (pricing, labeling) typically stop updating for it. Other package sizes or other manufacturers' versions of the same medication may still be marketed — see the equivalents section where available.
Is the NDC printed on the package the same as the 11-digit billing NDC?
Yes, they identify this exact package in different formats. The form printed on the packaging and shown on DailyMed is the one the FDA registered. Insurance claims use a fixed 11-digit 5-4-2 format, so the short segment is padded with a leading zero and the dashes are dropped. The Identity section at the top of this page lists each form of this code.
Who lists this product with the FDA?
Eli Lilly and Company is the labeler of record for this NDC — the company under whose FDA-assigned code the package is listed. The labeler may be the manufacturer itself or a distributor marketing the product under its own code.
Do I need a prescription for this product?
This NDC is listed with FDA as a prescription product, so it is dispensed under a prescriber's order. Your pharmacist can tell you whether any over-the-counter forms of the same medication exist.
This page identifies an FDA-listed package (the NDC) and reports public regulatory and pricing data about the listing. It is reference information, not a medical recommendation — talk to your pharmacist or prescriber about your own medication.
Where does this data come from?
Listing facts (marketing category, packager status, marketing dates) from the FDA openFDA NDC Directory; label availability from DailyMed; pricing coverage from CMS NADAC; equivalence scope from the FDA Orange Book.
← 00002-4103-11 · Eli 00002-4178-31 · Eli →
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.